Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Foresee Pharmaceuticals Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6576'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.67 Med: -0.25 Max: -0.03
Current: -4.67
During the past 12 years, the highest Debt-to-EBITDA Ratio of Foresee Pharmaceuticals Co was -0.03. The lowest was -4.67. And the median was -0.25.
ROCO:6576's Debt-to-EBITDA is ranked worse than 100% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs ROCO:6576: -4.67
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Foresee Pharmaceuticals Co Debt-to-EBITDA Related Terms
Foresee Pharmaceuticals Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Foresee Pharmaceuticals Co (ROCO:6576) has a Debt-to-EBITDA of 0.23 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Foresee Pharmaceuticals Co. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #999999 out of 685 companies in the Drug Manufacturers industry.
Is Foresee Pharmaceuticals Co's Debt-to-EBITDA too high?
Foresee Pharmaceuticals Co's current Debt-to-EBITDA is 0.23. The Drug Manufacturers industry median Debt-to-EBITDA is 1.58. Foresee Pharmaceuticals Co's value of 0.23 is 85.4% below this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #999999 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #999999 out of 685 companies for Debt-to-EBITDA. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.58. Foresee Pharmaceuticals Co's value of 0.23 is 85.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current Debt-to-EBITDA of 0.23 is 85.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Foresee Pharmaceuticals Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current Debt-to-EBITDA is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Fairly Valued. The stock's GF Value™ is NT$84.30, compared to a current price of NT$79.40 — trading 5.8% below its estimated fair value. The current Debt-to-EBITDA is 0.23 and 85.4% below the Drug Manufacturers industry median of 1.58. Foresee Pharmaceuticals Co's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Debt-to-EBITDA is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$79.40 is trading 5.8% below its estimated GF Value™ of NT$84.30.
GuruFocus considers Foresee Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for ROCO:6576:
Debt-to-EBITDA: 0.23
GF Value™: NT$84.30 vs. price of NT$79.40 (5.8% below fair value)
Industry Position: 85.4% below the Drug Manufacturers median (#999999 of 685)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
61GF Score
Get the complete analysis for ROCO:6576
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
